190 related articles for article (PubMed ID: 34530148)
21. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study.
Comer GC; Smith MW; Hurwitz EL; Mitsunaga KA; Kessler R; Carragee EJ
Spine J; 2012 Oct; 12(10):881-90. PubMed ID: 23098617
[TBL] [Abstract][Full Text] [Related]
22. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
Glassman SD; Gum JL; Crawford CH; Shields CB; Carreon LY
Spine J; 2011 Jun; 11(6):522-6. PubMed ID: 20598649
[TBL] [Abstract][Full Text] [Related]
23. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2.
Pradhan BB; Bae HW; Dawson EG; Patel VV; Delamarter RB
Spine (Phila Pa 1976); 2006 May; 31(10):E277-84. PubMed ID: 16648733
[TBL] [Abstract][Full Text] [Related]
24. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
Roh JS; Yeung CA; Field JS; McClellan RT
J Orthop Surg Res; 2013 Dec; 8():49. PubMed ID: 24373225
[TBL] [Abstract][Full Text] [Related]
26. Meta-Analysis on Efficacy and Complications of Bone Morphogenetic Protein-2 for Posterior Fusion of Cervical Spine.
Lee HR; Lee DH; Seok SY; Kim IH; Cho JH; Hwang CJ
World Neurosurg; 2024 Mar; 183():e3-e10. PubMed ID: 37741335
[TBL] [Abstract][Full Text] [Related]
27. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions.
Vaidya R; Sethi A; Bartol S; Jacobson M; Coe C; Craig JG
J Spinal Disord Tech; 2008 Dec; 21(8):557-62. PubMed ID: 19057248
[TBL] [Abstract][Full Text] [Related]
28. Ultra-low-dose recombinant human bone morphogenetic protein-2 for 3-level anterior cervical diskectomy and fusion.
Pourtaheri S; Hwang K; Faloon M; Issa K; Mease SJ; Mangels D; Sinha K; Emami A
Orthopedics; 2015 Apr; 38(4):241-5. PubMed ID: 25901613
[TBL] [Abstract][Full Text] [Related]
29. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis.
Crawford CH; Carreon LY; McGinnis MD; Campbell MJ; Glassman SD
Spine (Phila Pa 1976); 2009 Jun; 34(13):1390-4. PubMed ID: 19440166
[TBL] [Abstract][Full Text] [Related]
30. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.
Faundez A; Tournier C; Garcia M; Aunoble S; Le Huec JC
Int Orthop; 2016 Jun; 40(6):1309-19. PubMed ID: 26961193
[TBL] [Abstract][Full Text] [Related]
31. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study.
Carragee EJ; Mitsunaga KA; Hurwitz EL; Scuderi GJ
Spine J; 2011 Jun; 11(6):511-6. PubMed ID: 21612985
[TBL] [Abstract][Full Text] [Related]
32. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
33. The Use of Bone Morphogenetic Protein in Spinal Transforaminal Lumbar Interbody Fusion: Our Experience.
Colom-Beauchamp E; Beaton-Comulada D; Rodriguez JA; Pérez-López JC; Montañez-Huertas J; Escobar-Medina E; Massanet-Vollrath J
P R Health Sci J; 2017 Sep; 36(3):173-178. PubMed ID: 28915307
[TBL] [Abstract][Full Text] [Related]
34. Is lumbar facet fusion biomechanically equivalent to lumbar posterolateral onlay fusion?
Toth JM; Foley KT; Wang M; Seim HB; Simon Turner A
J Neurosurg Spine; 2017 May; 26(5):586-593. PubMed ID: 28156207
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.
Choi JY; Park HJ; Park SM; Kang CN; Song KS
J Orthop Surg Res; 2022 Aug; 17(1):397. PubMed ID: 36045371
[TBL] [Abstract][Full Text] [Related]
36. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
Rahman RK; Buchowski JM; Stephens B; Dorward IG; Koester LA; Bridwell KH
Spine (Phila Pa 1976); 2013 Dec; 38(26):2264-71. PubMed ID: 24108280
[TBL] [Abstract][Full Text] [Related]
37. Off-label innovation: characterization through a case study of rhBMP-2 for spinal fusion.
Schnurman Z; Smith ML; Kondziolka D
J Neurosurg Spine; 2016 Sep; 25(3):406-14. PubMed ID: 27104282
[TBL] [Abstract][Full Text] [Related]
38. Anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2: a prospective study of complications.
Malham GM; Parker RM; Ellis NJ; Blecher CM; Chow FY; Claydon MH
J Neurosurg Spine; 2014 Dec; 21(6):851-60. PubMed ID: 25279655
[TBL] [Abstract][Full Text] [Related]
39. The minimally effective dose of bone morphogenetic protein in posterior lumbar interbody fusion: a systematic review and meta-analysis.
Lytle EJ; Lawless MH; Paik G; Tong D; Soo TM
Spine J; 2020 Aug; 20(8):1286-1304. PubMed ID: 32339767
[TBL] [Abstract][Full Text] [Related]
40. Pseudo-Pedicle Heterotopic Ossification From Use of Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2) in Transforaminal Lumbar Interbody Fusion Cages.
Rosen CD; Kiester PD; Lee TQ
Am J Orthop (Belle Mead NJ); 2018 Jan; 47(1):. PubMed ID: 29447305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
